AstraZeneca Is Getting Into the Weight-Loss Drug Game. The Stock Needs a Boost.
AstraZeneca has struck a licensing deal worth up to $2 billion for a weight-loss drug. Stockholders are welcoming the move as its shares have lagged behind peers Eli Lilly and Novo Nordisk.
AstraZeneca Paying Up To $2 Billion For Experimental Obesity Pill—As Weight Loss Drug Market Grows
The drug is similar to Ozempic, which is commonly used for diabetes and weight loss.
AstraZeneca: "Take some reassurance” from obesity drug bet
AstraZeneca PLC (LSE:AZN) has upgraded its sales forecast for the year, in the hope that its foray into a semaglutide obesity drug will make up for concerns over its Covid-19 vaccine and bolster sa...
AstraZeneca raises stakes in obesity drug race with Eccogene deal
AstraZeneca moved on Thursday to boost its drugs pipeline in the booming anti-obesity market, saying it would pay China's Eccogene up to about $2 billion for an exclusive licence to develop an expe...
AZ shares up 2% after it tweaks FY guidance higher
Shares of AstraZeneca PLC (LSE:AZN) rose 2% following the upward revision to its full-year core earnings per share (EPS) and revenue forecasts. The Anglo-Swedish pharma giant now anticipates a low ...
AstraZeneca ups annual outlook on strong cancer drugs demand
Drugmaker AstraZeneca raised its annual core profit outlook on Thursday, helped by strong demand for its oncology and rare blood disorder drugs.
AstraZeneca results offer chance to set itself apart from rivals after FTSE 100 crown slips
AstraZeneca PLC (LSE:AZN) approaches its third-quarter update with its shares having slipped 15% from the all-time highs reached in the spring, when it jostled back past Shell to regain top spot of...
AstraZeneca inks gene editing deal that could end up costing it $2.5bn
AstraZeneca PLC (LSE:AZN) has entered into a partnership and investment deal with French gene editing specialist biotech firm Cellectis (NASDAQ:CLLS) which it hopes will speed up the development of...
AstraZeneca signs drug development deal with biotech Cellectis
AstraZeneca said on Wednesday it had entered into a collaboration and investment agreement with clinical-stage biotechnology company Cellectis to speed up the development of therapeutics in areas i...
Astrazeneca (AZN) Rises But Trails Market: What Investors Should Know
In the most recent trading session, Astrazeneca (AZN) closed at $63.23, indicating a +0.46% shift from the previous trading day.
3 No-Brainer Stocks to Buy for Under $100 Right Now
AstraZeneca's slump presents a great buying opportunity. BioNTech's future prospects go well beyond COVID-19.
These healthcare stocks should come to life as boomers live their golden years
Baby boomers: Love ‘em or hate ‘em, the juggernaut generation changes every aspect of life it steamrolls through. Now it's doing the same to healthcare.
Barclays and AstraZeneca up staff pay as Real Living Wage increases
Employers which pay staff the Real Living Wage (RLW) will have to find an extra 10% after it was increased to £12 in the UK and £13.10 in London on Tuesday. Providing workers with a salary that is ...
AstraZeneca said U.S. FDA has accepted for review its Flumist self-administered flu vaccine
AstraZeneca PLC AZN, -1.22% AZN, +1.45% said Tuesday the U.S. Food and Drug Administration has accepted its application for approval of a self-administered flu vaccine. The company said the regulat...
US FDA accepts AstraZeneca's self-administered flu vaccine for review
AstraZeneca said on Tuesday the U.S. Food and Drug Administration (FDA) has accepted for review the company's application seeking approval for patients or caregivers to administer its nasal flu vac...
Related Companies